Dacogen

This page shows the latest Dacogen news and features for those working in and with pharma, biotech and healthcare.

Otsuka to buy cancer biopharma Astex

Takes control of company behind Dacogen in $886m deal. Japanese pharma firm Otsuka has agreed to purchase cancer specialist Astex Pharmaceuticals in a deal worth $886m. ... Astex' lead product is Dacogen (decitabine), which is approved for the treatment

Latest news

Cancer data presented at ASCO

Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).
J&J positive about pipeline

this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.
SuperGen and Astex to merge

It plans to leverage a revenue stream from its product Dacogen, marketed in North America by Eisai and in the rest of the world by Johnson &Johnson.
New accounts: May

Dacogen. Haematology. Darwin Grey. Midatech. Glyconanoparticles. Cancer vaccines. Healthcare Solutions. National Health Service.
The Pump House

Dacogen (MGI Pharma). Myelodysplastic syndromes. US. Granisetron. Generic granisetron (Actavis Group).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.